Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: USP10

Gene summary for USP10

Gene summary.

Gene information	Species	Human
	Gene symbol	USP10
	Gene ID	9100
	Gene name	ubiquitin specific peptidase 10
	Gene Alias	UBPO
	Cytomap	16q24.1
	Gene Type	protein-coding
	GO ID	GO:0000731
	UniProtAcc	Q14694

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9100	USP10	LZE2T	Human	Esophagus	ESCC	6.65e-03	7.39e-01	0.082
9100	USP10	LZE4T	Human	Esophagus	ESCC	2.01e-23	7.90e-01	0.0811
9100	USP10	LZE7T	Human	Esophagus	ESCC	7.41e-11	6.87e-01	0.0667
9100	USP10	LZE8T	Human	Esophagus	ESCC	5.54e-12	3.41e-01	0.067
9100	USP10	LZE20T	Human	Esophagus	ESCC	1.99e-05	9.52e-02	0.0662
9100	USP10	LZE22T	Human	Esophagus	ESCC	1.04e-02	2.14e-01	0.068
9100	USP10	LZE24T	Human	Esophagus	ESCC	1.50e-12	4.96e-01	0.0596
9100	USP10	LZE21T	Human	Esophagus	ESCC	1.81e-02	3.77e-01	0.0655
9100	USP10	LZE6T	Human	Esophagus	ESCC	3.66e-05	1.70e-01	0.0845
9100	USP10	P1T-E	Human	Esophagus	ESCC	2.53e-04	5.62e-01	0.0875
9100	USP10	P2T-E	Human	Esophagus	ESCC	1.01e-31	6.22e-01	0.1177
9100	USP10	P4T-E	Human	Esophagus	ESCC	1.45e-23	5.98e-01	0.1323
9100	USP10	P5T-E	Human	Esophagus	ESCC	1.33e-20	5.15e-01	0.1327
9100	USP10	P8T-E	Human	Esophagus	ESCC	4.49e-26	6.35e-01	0.0889
9100	USP10	P9T-E	Human	Esophagus	ESCC	9.94e-12	3.36e-01	0.1131
9100	USP10	P10T-E	Human	Esophagus	ESCC	2.47e-21	2.59e-01	0.116
9100	USP10	P11T-E	Human	Esophagus	ESCC	2.57e-07	5.31e-01	0.1426
9100	USP10	P12T-E	Human	Esophagus	ESCC	3.71e-18	4.73e-01	0.1122
9100	USP10	P15T-E	Human	Esophagus	ESCC	3.27e-30	8.75e-01	0.1149
9100	USP10	P16T-E	Human	Esophagus	ESCC	2.43e-28	4.80e-01	0.1153

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001050617	Esophagus	ESCC	regulation of autophagy	220/8552	317/18723	6.72e-18	6.36e-16	220
GO:0072331111	Esophagus	ESCC	signal transduction by p53 class mediator	121/8552	163/18723	9.61e-14	4.69e-12	121
GO:0010563111	Esophagus	ESCC	negative regulation of phosphorus metabolic process	274/8552	442/18723	2.32e-12	9.41e-11	274
GO:0045936111	Esophagus	ESCC	negative regulation of phosphate metabolic process	273/8552	441/18723	3.18e-12	1.25e-10	273
GO:0043122110	Esophagus	ESCC	regulation of I-kappaB kinase/NF-kappaB signaling	167/8552	249/18723	6.11e-12	2.32e-10	167
GO:007189716	Esophagus	ESCC	DNA biosynthetic process	127/8552	180/18723	1.04e-11	3.85e-10	127
GO:0051348111	Esophagus	ESCC	negative regulation of transferase activity	177/8552	268/18723	1.08e-11	4.00e-10	177
GO:007190016	Esophagus	ESCC	regulation of protein serine/threonine kinase activity	227/8552	359/18723	1.12e-11	4.10e-10	227
GO:000724919	Esophagus	ESCC	I-kappaB kinase/NF-kappaB signaling	183/8552	281/18723	3.02e-11	1.01e-09	183
GO:0042326111	Esophagus	ESCC	negative regulation of phosphorylation	237/8552	385/18723	1.86e-10	5.33e-09	237
GO:0001933111	Esophagus	ESCC	negative regulation of protein phosphorylation	213/8552	342/18723	3.54e-10	9.76e-09	213
GO:001631110	Esophagus	ESCC	dephosphorylation	251/8552	417/18723	1.26e-09	2.99e-08	251
GO:003367319	Esophagus	ESCC	negative regulation of kinase activity	154/8552	237/18723	1.38e-09	3.27e-08	154
GO:000646920	Esophagus	ESCC	negative regulation of protein kinase activity	140/8552	212/18723	1.53e-09	3.56e-08	140
GO:004277014	Esophagus	ESCC	signal transduction in response to DNA damage	117/8552	172/18723	2.38e-09	5.32e-08	117
GO:000647018	Esophagus	ESCC	protein dephosphorylation	177/8552	281/18723	3.13e-09	6.72e-08	177
GO:004578527	Esophagus	ESCC	positive regulation of cell adhesion	255/8552	437/18723	5.07e-08	9.11e-07	255
GO:003109818	Esophagus	ESCC	stress-activated protein kinase signaling cascade	154/8552	247/18723	8.53e-08	1.44e-06	154
GO:005140318	Esophagus	ESCC	stress-activated MAPK cascade	147/8552	239/18723	5.43e-07	7.18e-06	147
GO:0030330110	Esophagus	ESCC	DNA damage response, signal transduction by p53 class mediator	53/8552	72/18723	1.34e-06	1.63e-05	53

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

USP10

SNV

Missense_Mutation

c.225N>T

p.Leu75Phe

p.L75F

Q14694

protein_coding

tolerated_low_confidence(0.36)

possibly_damaging(0.517)

TCGA-D8-A1JF-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

USP10

SNV

Missense_Mutation

rs373590750

c.1790G>A

p.Arg597His

p.R597H

Q14694

protein_coding

deleterious(0.03)

possibly_damaging(0.471)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

USP10

insertion

In_Frame_Ins

novel

c.1844_1844+1insCAT

p.Arg615delinsSerMet

p.R615delinsSM

Q14694

protein_coding

TCGA-A8-A06P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unspecific

USP10

insertion

Nonsense_Mutation

novel

c.1542_1543insGTCTTGGTTAGGTCAAGTTCTTGAATACA

p.Asn515ValfsTer8

p.N515Vfs*8

Q14694

protein_coding

TCGA-AN-A0FW-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

USP10

insertion

Frame_Shift_Ins

novel

c.1114_1115insATGGA

p.Ala372AspfsTer27

p.A372Dfs*27

Q14694

protein_coding

TCGA-AO-A0JD-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

USP10

SNV

Missense_Mutation

c.1934G>A

p.Arg645His

p.R645H

Q14694

protein_coding

tolerated(0.25)

benign(0.038)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

USP10

SNV

Missense_Mutation

c.629N>T

p.Pro210Leu

p.P210L

Q14694

protein_coding

deleterious_low_confidence(0.04)

possibly_damaging(0.651)

TCGA-DS-A7WF-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

USP10

SNV

Missense_Mutation

rs780433322

c.1783G>A

p.Val595Ile

p.V595I

Q14694

protein_coding

tolerated(0.51)

benign(0.037)

TCGA-AA-3510-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

USP10

SNV

Missense_Mutation

c.1256G>A

p.Arg419His

p.R419H

Q14694

protein_coding

deleterious(0.03)

probably_damaging(0.972)

TCGA-AA-3852-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

USP10

SNV

Missense_Mutation

c.478N>T

p.Pro160Ser

p.P160S

Q14694

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.978)

TCGA-AA-3864-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1